History
Preview
Next view
JW Group has started its steps with the restoration of nation’s independence
JW Group’s footstep which has brought about the great accomplishment Represents the history of Korea’s pharmaceutical industry.-
2020
- Obtainment of a US patent for an early diagnosis technology of pancreatic cancer
- Joint development of a next-generation nutrient sap with Baxter
- Conclusion of the Winuf® exclusive technology exportation and provision agreement with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. in China
-
2019
- C&C Research Laboratories, JW Pharmaceutical Subsidiary transfer
- Signed a technology export contract with the Simcere
company in China,'URC102' for gout treatment - Acquired 'Euvipharm', the first Vietnamese pharmaceutical
company in Korea - Atopic dermatitis ‘JW1601’ won the ‘Technology Exporter’
and the 'King Sejong the Great', the highest patented
technology in Korea - Acquired patents for China and Europe for early diagnosis
of pancreatic cancer - A hemophilia drug 'hemri Bra' rare drug designation and
market sales permit - Asia’s first sell a three-chamber nutrient infusion in EU
-
2018
- JW Life Science Industry First "Nutrient Toolking" in Asia Get EU
– GMP - Technology export of atopic dermatitis drug 'JW1601'
- JW Life Science Industry First "Nutrient Toolking" in Asia Get EU
-
2017
- 2017 Signed export contract for ‘Ertapenem’,
the next generation antibiotic with Gland Pharma from India
- 2017 Signed export contract for ‘Ertapenem’,
-
2016
- JW Lifescience listed on Securities Market
-
2015
- Vision 70+5 Declaration
-
2013
- Signed Export Agreement with America’s Baxter for 3-Chamber
Nourishment Transfusion Fluid - Joint-Development agreement with Japan’s SKK worth 100 billion
for pharmaceutical products - Founded True Medical Personnel respecting life,
enacted ‘Sungcheon Award’
- Signed Export Agreement with America’s Baxter for 3-Chamber
-
2012
- Relocation of C&C new medicine research institute
- (DRC hall, Sungkyunkwan University,
Suwon natural science campus)
-
2011
- Renamed to JW Holdings Corporation
- Renamed to JW Pharmaceutical Corporation
- Renamed to JW Shinyak Corporation
- Renamed to JW Life Science Corporation
- Renamed to JW Medical Corporation
- Renamed to JW Living Healthcare Corporation
-
2010
- JW Dangjin Production Complex, which is Korea’s largest
Medicine-manufacturing plant, was built
- JW Dangjin Production Complex, which is Korea’s largest
-
2009
- JW Shinyak was listed on the KOSDAQ
- Awarded US$30 mil-Export Tower
-
2008
- Took over Three-Seven
- Certified as Good Labor Culture Enterprise from Labor Ministry
- Eco-friendly B1 established
-
2007
- Awarded Presidential Citation on the occasion of Environment Day
- Choongwae Holdings established
-
2006
- World’s largest Non-PVC supplement plant (Dangjin) was built
-
2005
- Designated as Korea’s 30-respectable enterprises
- (Dong-A Ilbo Daily, IBM BCS)
- Designated as Asia’s 200 outstanding enterprises (Fobes Asia)
- Choongwae Shinyak established
-
2004
- Antibiotics, ‘Impenem’ first generic with US$600 mil-scale potential
- Global market developed
- Impenem plant meeting EU GMP standard was built (Sihwa)
-
2003
- Awarded the 3rd Gyeonggi Green Environment Trophy
(Gyeonggi Province) - Awarded the 4th Korea Business Image Grand Prize by KMAC
- Awarded the 5th Industrial Peace Grand Prize
- Awarded the 3rd Gyeonggi Green Environment Trophy
-
2002
- Awarded New Medicine Development Prize with Balofloxacin
(Ginko biloba leaf extract) - Antibiotics Ketoconnazole was certified by Europe COS
- Awarded New Medicine Development Prize with Balofloxacin